All News
Filter News
Found 101 articles
-
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
8/14/2023
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today reported financial results and business highlights for the second quarter ended June 30, 2023.
-
Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023
8/4/2023
Sosei Group Corporation provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2023.
-
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
7/10/2023
Centessa Pharmaceuticals plc today announced the dosing of the first subject in its registrational PRESent-2 study of SerpinPC for the treatment of hemophilia B without inhibitors.
-
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - May 24 2023
5/24/2023
Centessa Pharmaceuticals plc today announced that members of its management team will participate in the following investor conferences.
-
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B
5/22/2023
Centessa Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SerpinPC, an investigational novel inhibitor of activated protein C (APC) being developed for the treatment of hemophilia B, with or without inhibitors.
-
Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2023
5/12/2023
Sosei Group Corporation provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2023.
-
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
5/12/2023
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today reported financial results and business highlights for the first quarter ended March 31, 2023.
-
Transgene’s Combined General Meeting of May 5, 2023
5/5/2023
The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held at 9:00 a.m. at the Company’s headquarters.
-
Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
4/12/2023
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the Board of Directors has proposed Ms.
-
HDAX Therapeutics Announces Appointment of Drs. Roman Fleck and Neal I. Muni to Board of Directors
4/11/2023
HDAX Therapeutics, Inc. announced the appointment of Roman Fleck, Ph.D. as Executive Chairman of the Board and Neal I. Muni, M.D., MSPH, as an independent Board member.
-
Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
3/30/2023
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today reported recent business progress and financial results for the fourth quarter and full-year ended December 31, 2022.
-
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - March 27, 2023
3/27/2023
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, announced that members of its management team will participate in the following investor conferences,.
-
Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
3/1/2023
Centessa Pharmaceuticals plc today announced the appointment of Patrick Yue, MD, to Centessa’s management team as Senior Vice President of Clinical Development, Innovative Medicines.
-
Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
2/6/2023
Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that the Company will present additional data from the open-label extension (OLE) of AP-0101, a Phase 2a study of SerpinPC, a novel inhibitor of activated protein C (APC) being developed for the treatment of hemophilia, during an oral presentation at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), on February 10, 2023.
-
Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference
2/2/2023
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that members of its management team will participate in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 8:00 a.m. ET.
-
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
1/26/2023
Centessa Pharmaceuticals plc today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2a first-in-human, clinical trial of LB101 for the treatment of solid tumors.
-
Full-Life Technologies Announces Appointment of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer
1/16/2023
Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).
-
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
12/10/2022
Centessa Pharmaceuticals plc, announced new data from an additional 18-months of continued treatment with SerpinPC, an investigational, subcutaneously administered novel inhibitor of activated protein C, from the open-label extension of the Phase 2a study of SerpinPC for hemophilia.
-
Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson
11/30/2022
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced Karen Anderson as its new Chief People Officer.
-
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
11/10/2022
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, reported financial results and business highlights for the third quarter ended September 30, 2022.